NEW YORK, Nov. 2 (GenomeWeb News) - Cellomics will collaborate with Max Planck Institute in high-content screening development for drug discovery, Cellomics said last week.
As part of the agreement, the Max Planck Institute of Molecular Cell Biology and Genetics, located in Dresden, Germany, has purchased the Cellomics' ArrayScan VTI HCS Reader along with its complete portfolio of BioApplications and HCi informatics software.
The collaboration will include a mix of applications and new product development, as well as establishing a key demonstration center for Europe, said Daniel J. Calco, Cellomics' president, in a statement.
Cellomics, a unit of Fisher Biosciences, provides a cell-based platform.